Back to comparisons

Comparison

NMN vs PQQ

FieldNMNPQQ
Categoryneuroprotectiveneuroprotective
Dose range250–1000mg10–40mg
Half-life
Onset
EvidenceEVIDENCEBEVIDENCEC
Safety●●●●●●●●●●
Legal (US)USOTCUSOTC
PubMed refs600320

The comparison in plain English

Auto-generated from data

NMN and PQQ are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide — NAD+ precursor. PQQ Pyrroloquinoline quinone — cofactor in mitochondrial biogenesis.

Bottom line

NMN (evidence B, safety 5/5) has a weaker evidence base than PQQ (evidence C, safety 5/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.

Choose NMN if

NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+ — one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is —h.

Choose PQQ if

PQQ is the better fit when your goal aligns with its mechanism (Pyrroloquinoline quinone uniquely stimulates mitochondrial biogenesis via the PGC-1α pathway — it doesn't just improve existing mitochondrial function but creates new mitochondria) and the dose range (10–40mg) suits your protocol. Half-life is —h.

Build a stack with bothOpen builder →
Check interactionsOpen checker →